[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"muscular-dystrophies\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:muscular-dystrophies":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,69,101,133,168,219,231,261,286,316,353,376,397,422],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":42,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":4},"100053565","phase-3-a-phase-3-study-to-evaluate-the-safety-and-efficacy-of-aoc-1044-also-referred-to-as-delpacibart-zotadirsen-in-participants-with-dmd-with-gene-mutations-amenable-to-exon-44-skipping-100053565",false,"NCT07587242","A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping","A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (Delpacibart Zotadirsen) for the Treatment of DMD With Gene Mutations Amenable to Exon 44 Skipping","SAFARI44","Key Inclusion Criteria:\n\n* Ambulatory males with clinical and genetic diagnosis of DMD\n* Acceptable genetic test confirming dystrophin gene mutation amenable to exon 44 skipping\n* 7 to 16 years of age at time of consent\n* TTR and NSAA assessment completed within the protocol specified parameters at Screening\n* On a stable regimen of corticosteroids (including Vamolorone) for at least 6 months prior to Day 1. Steroid regimen must be anticipated to remain stable.\n\nKey Exclusion Criteria:\n\n* Previous treatment cell or gene therapy.\n* Treatment with another oligonucleotide within 6 months of informed consent (not including COVID-19 RNA vaccines).\n* Lab values outside of the protocol specified range at Screening\n* If on any of the following treatments (growth hormone, testosterone or givinostat), participants must be on a stable regimen and must plan to maintain it for the duration of the study. Participants will be excluded if regimen stability prior to informed consent is as follows:\n* Less than 1 month, for growth hormone and\u002For testosterone\n* Less than 6 months for givinostat","MALE","7 Years","16 Years",{"count":21,"type":22},70,"ESTIMATED","INTERVENTIONAL",[25],"PHASE3","A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Intravenous AOC 1044 for the treatment of Duchenne Muscular Dystrophy (DMD) with Gene Mutations Amenable to Exon 44 Skipping",[28,29,30,31,32,33,34,35,36,37,38,39,40,41],"Muscular Dystrophies","Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)","Muscular Disorders, Atrophic","Muscular Disease","Musculoskeletal Diseases","Neuromuscular Diseases (NMD)","Nervous System Diseases","Genetic Diseases","X-Linked","Hereditary","Neonatal Disease","Duchene Muscular Dystrophy","Congenital","DMD",[43,44,45,46,47,48,49,50,15,51,52,53,54,55,56,41],"AOC","AOC 1044","AOC 1044-CS3","AOC 1044-CS1","AOC 1044-CS2","EXPLORE44","EXPLORE44-OLE","SAFARI","SAFARI 44","Avidity","Avidity Biosciences","Exon Skipping Therapy","Avidity Biosciences Inc., A Novartis Company","del-zota","NOT_YET_RECRUITING","2026-07-10",{"date":60,"type":61},"2026-07-13","ACTUAL",{"date":63,"type":22},"2026-06",{"date":65,"type":22},"2030-07",{"name":67,"class":68},"Avidity Biosciences, Inc.","INDUSTRY",{"id":70,"slug":71,"hasResults":11,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":4,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":76,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":77,"phases":4,"briefSummary":78,"conditions":79,"keywords":85,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":100,"locationsCount":5},"100612219","managed-access-program-for-del-zota-in-participants-with-dmd-mutations-amenable-to-exon-44-skipping-100612219","NCT07250737","Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping","Managed Access to Investigational Use of AOC 1044 in Participants With DMD Mutations Amenable to Exon 44 Skipping","Key Inclusion Criteria\n\nRollover Participants\n\n* Completed Study EXPLORE44-OLE Treatment Period (through W102)\n* No significant tolerability issues with AOC 1044\n\nNew (Non-Rollover) Participants\n\n* Permanently residing in the US and have a US primary health care provider\n* Documented dystrophin gene mutation that is amenable to exon 44 skipping\n* Age 2 or older at the time of consent\n* If previously treated with gene therapy for DMD, treatment and associated immunosuppressive regimen was more than 12 months before consent and in the opinion of the prescriber, participant has had an unsatisfactory treatment response\n\nKey Exclusion Criteria\n\nRollover Participants\n\n• Prescence of any new condition or worsening of existing condition that could affect participant's safety or ability to comply with the program requirements\n\nNew (Non-Rollover) Participants\n\n* Recently treated with or on a clinical study for another investigation drug\n* Serious respiratory or cardiac dysfunction, or nearing end of life\n* Screening laboratory parameters do not meet protocol requirements\n* History of multiple drug allergies or to any component of AOC 1044\n* Participants who discontinued early from the treatment period of EXPLORE44 or EXPLORE44-OLE","2 Years","EXPANDED_ACCESS","The purpose of this Managed Access Program is to allow access to delpacibart zotadirsen (AOC 1044) for eligible patients diagnosed with DMD mutations amenable to exon 44 skipping. The patient's Administering Physician should follow the suggested treatment guidelines and comply with all local health authority regulations.",[30,80,32,81,34,82,83,28,84],"Muscular Diseases","Neuromuscular Diseases","Genetic Diseases, Inborn","Genetic Diseases, X-Linked","Muscular Dystrophy, Duchenne",[52,53,44,46,47,48,49,86,87,41,88,89,90,91,92,93,94,95],"Del-zota","delpacibart zotadirsen","exon skipping therapy","dystrophin","managed access","expanded access","pre-approval access","compassionate use","MAP","EAP","AVAILABLE","2026-06-26",{"date":99,"type":61},"2026-06-29",{"name":67,"class":68},{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":23,"phases":112,"briefSummary":114,"conditions":115,"keywords":118,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":132},"100615022","phase-2-phase-2-study-of-sat-3247-in-pediatric-ambulatory-patients-100615022","NCT07287189","Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients","A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Dose Comparison and Exploratory Efficacy Study of Orally Administered SAT-3247 in Ambulatory DMD Patients","BASECAMP","Key Inclusion Criteria:\n\n* Has a definitive diagnosis of DMD based on documented clinical findings and prior genetic testing with a confirmed mutation in the DMD gene.\n* Male DMD patients who are ambulatory and aged ≥ 7 to \\\u003C 10 years at the time of screening.\n* Stable dose of systemic glucocorticoids (i.e., prednisolone, deflazacort, or vamorolone) according to the standard of care for ≥ 3 months prior to the Screening Visit and for the duration of the trial. Patients who are not receiving glucocorticosteroids are also eligible if stopped ≥ 3 months prior to the Screening Visit.\n* Stable doses of prescription medicines including ACE inhibitors, β-blockers, and diuretics (excluding glucocorticosteroids) and over-the-counter medicines and\u002For herbal supplements for supportive care ≥ 1 month prior to the Screening Visit and for the duration of the trial.\n* Participants that have previously received delandistrogene moxeparvovec (brand name Elevidys) either in a prior clinical trial or in the commercial setting \\> 18 months prior to screening whose muscle function tests have stabilized or demonstrated decline ≥ 3 months prior to Screening, as determined by investigator and documented in chart notes, will be eligible.\n* Participants that have previously received an exon skipper \\> 6 months prior to Screening whose muscle function tests have stabilized or demonstrated decline ≥ 3 months prior to Screening, as determined by investigator and documented in chart notes, will be eligible.\n* Participants receiving a stable dose of givinostat (brand name Duvyzat) for at least 18 months or longer prior to the Screening Visit will be eligible. Participants unable to tolerate givinostat who discontinued treatment before 18 months are eligible to enroll if date of last dose is ≥ 30 days from the Screening date. Givinostat should not be discontinued, if tolerated, to meet study entry criteria.\n* Participants that have received prior treatment with an investigational gene therapy product (other than delandistrogene moxeparvovec) ≥ 24 months prior to the Screening Visit.\n* If participating in a physical therapy\u002Fstrength training regimen, must be stable for ≥ 2 months prior to the Screening Visit and for the duration of the trial.\n\nKey Exclusion Criteria:\n\n* Ambulatory patients expected to experience loss of ambulation within ≤ 12 months.\n* Participants for whom MRI or open muscle biopsy are contraindicated.\n* Evidence of significant hepatic dysfunction, defined as GLDH \\> 2X upper limit of normal (ULN) at the Screening Visit.\n* Impaired cardiac function defined as a left ventricular ejection fraction of \\\u003C 50% on screening cardiac assessments (echocardiogram or MRI) or evidence of symptomatic cardiomyopathy.\n* A forced vital capacity \\\u003C 60% predicted at the Screening Visit.\n* Ongoing participation in any other therapeutic clinical trial or follow-up study for a therapeutic intervention\n* Consumption of grapefruit juice or grapefruit containing products\n* Severe behavioural or cognitive problems that preclude participation in the study, in the opinion of the investigator.\n\nAdditional entry criteria will be reviewed with the clinical site investigator.","9 Years",{"count":111,"type":22},51,[113],"PHASE2","Phase 2a trial of SAT-3247 in ambulatory DMD patients aged ≥ 7 and \\\u003C 10 years. The trial will study two doses of SAT-3247 in a randomized, double-blind, placebo-controlled weekday regimen for 12 weeks to determine the optimal dose, safety, tolerability, and preliminary efficacy.",[116,117,41,81,28],"Duchenne Muscular Dystrophy","Duchenne",[119,120,121,89],"muscle regeneration","satellite cell","asymmetric division","RECRUITING","2026-06-12",{"date":125,"type":61},"2026-06-16",{"date":127,"type":61},"2025-12-08",{"date":129,"type":22},"2027-06-30",{"name":131,"class":68},"Satellos Bioscience, Inc.",21,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":139,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":141,"minAge":142,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":23,"phases":146,"briefSummary":148,"conditions":149,"keywords":4,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":167},"100494899","feasibility-of-the-braingate2-neural-interface-system-in-persons-with-tetraplegia-100494899","NCT05724173","Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia","Single Neuron Population Dynamics in Human Speech Motor Cortex for a Speech Prosthesis","BG-Speech-01","Inclusion Criteria:\n\n* Between 18 and 80 years of age.\n* Participants must have a diagnosis of amyotrophic lateral sclerosis (ALS) as verified by a clinical expert in neurologic diseases.\n* Participants with a diagnosis of ALS with anarthria, or severe dysarthria with decline in the preceding four months.\n* Must be within a three-hour drive of the Study site and geographically stable for at least 15 months after enrollment.\n\nExclusion Criteria:\n\n* Visual impairment such that extended viewing of a computer monitor would be difficult even with ordinary corrective lenses\n* Chronic oral or intravenous steroids or immunosuppressive therapy\n* Other serious disease or disorder that could seriously affect ability to participate in the study\n\n(There are additional exclusion criteria)","ALL","18 Years","80 Years",{"count":145,"type":22},3,[147],"NA","The purpose of this study is to obtain preliminary device safety information and demonstrate proof of principle (feasibility) of the ability of people with tetraplegia to control a computer cursor and other assistive devices with their thoughts.",[150,151,152,153,154,155,156,28],"Anarthria","Dysarthria","Tetraplegia","Spinal Cord Injuries","Amyotrophic Lateral Sclerosis","Brain Stem Infarctions","Locked in Syndrome","2026-05-29",{"date":159,"type":61},"2026-06-02",{"date":161,"type":61},"2023-10-18",{"date":163,"type":22},"2027-07-31",{"name":165,"class":166},"Leigh R. Hochberg, MD, PhD.","OTHER",2,{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":11,"sex":17,"minAge":176,"maxAge":142,"enrollmentInfo":177,"targetDuration":4,"studyType":23,"phases":179,"briefSummary":180,"conditions":181,"keywords":190,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":215,"leadSponsor":217,"locationsCount":218},"100638348","phase-3-efficacy-safety-and-tolerability-of-zeleciment-rostudirsen-dyne-251-administered-intravenously-every-4-weeks-in-ambulatory-participants-with-duchenne-muscular-dystrophy-forzetto-100638348","NCT07608432","Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of DYNE-251 Administered Intravenously in Ambulatory Male Participants 4 to 18 Years of Age With Duchenne Muscular Dystrophy Amenable to Exon-51 Skipping","FORZETTO","Inclusion Criteria:\n\n* Ambulatory male with confirmed diagnosis of DMD and with a mutation in the dystrophin gene characterized by exon deletion amenable to exon 51 skipping .\n* Rise From Floor (RFF) time must be \\\u003C 10 seconds for both screening assessments .\n* Receiving a stable daily or weekend dosage of glucocorticoids for at least 24 weeks prior to randomization with the expectation of maintaining a stable dose during the Placebo-Controlled Period of the study (unless dose adjustment is required by weight change)\n\nExclusion Criteria:\n\n* Receipt of ongoing immunosuppressive therapy (other than glucocorticoids) within 12 weeks prior to randomization\n* Use of any pharmacologic treatment (other than glucocorticoids) that may have an effect on muscle strength or function within 12 weeks prior to randomization\n* Any change in prophylaxis\u002Ftreatment for congestive heart failure (CHF) within 12 weeks prior to randomization\n* Receipt of eteplirsen within 1 week prior to randomization\n* Receipt of alternative exon-skipping or dystrophin-modifying therapy or zeleciment rostudirsen within 24 weeks prior to randomization\n* Receipt of givinostat within 12 weeks prior to randomization\n* Receipt of gene therapy at any time\n\nNote: Other inclusion or exclusion criteria may apply","4 Years",{"count":178,"type":22},90,[25],"The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment rostudirsen (DYNE-251) administered intravenously (IV) every 4 weeks to ambulatory Duchenne muscular dystrophy (DMD) participants, 4 to 18 years of age, with dystrophin mutations amenable to exon 51 skipping.",[182,84,183,41,28,184,185,186,29,187,188,189,33],"Duchenne Muscular Dystrophy (DMD)","Muscular Dystrophy (DMD)","Muscular Dystrophy in Children","Muscular Dystrophy, Duchenne Type","Muscular Dystrophy, Duchenne and Becker Types","Genetic Disease, Inborn","Genetic Disease, X-Linked","Congenital, Hereditary, and Neonatal Diseases and Abnormalities",[191,41,116,117,192,193,194,195,196,197,174,198,199,200,201,202,203,204,205,206,207,208,209,210],"Ambulatory","Dyne","Dyne Therapeutics","DYNE-251","Dystrophy","Exon Skipping","Exon 51","Pediatric","PMO","Muscle Function","Muscular Dystropy, Duchenne","Rise From Floor","RFF","RFF Velocity","Rostudirsen","Time to rise","TTR","TTR Velocity","Zeleciment rostudirsen","Z-rostudirsen","2026-05-20",{"date":213,"type":61},"2026-05-27",{"date":63,"type":22},{"date":216,"type":22},"2032-10",{"name":193,"class":68},1,{"id":220,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":221,"targetDuration":4,"studyType":23,"phases":222,"briefSummary":26,"conditions":223,"keywords":224,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":225,"lastUpdatePostDateStruct":226,"startDateStruct":228,"completionDateStruct":229,"leadSponsor":230,"locationsCount":4},"100638788",{"count":21,"type":22},[25],[28,29,30,31,32,33,34,35,36,37,38,39,40,41],[43,44,45,46,47,48,49,50,15,51,52,53,54,55,56,41],"2026-05-08",{"date":227,"type":61},"2026-05-14",{"date":63,"type":22},{"date":65,"type":22},{"name":67,"class":68},{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":141,"minAge":238,"maxAge":142,"enrollmentInfo":239,"targetDuration":4,"studyType":23,"phases":241,"briefSummary":242,"conditions":243,"keywords":246,"overallStatus":57,"whyStopped":4,"lastUpdateSubmitDate":252,"lastUpdatePostDateStruct":253,"startDateStruct":255,"completionDateStruct":256,"leadSponsor":258,"locationsCount":260},"100639648","virtualparkpediatric-100639648","NCT07580365","VirtualPark_Pediatric","Evaluation of the Impact of a Rehabilitation Intervention Based on Cycling With Virtual Park on Slowing the Functional Motor Decline of Neuromuscular Patients in Developmental Age","Inclusion Criteria:\n\n* availability of a definitive clinical or molecular genetic diagnosis of a neuromuscular disease;\n* age between 6 years and 17 years and 11 months (inclusive);\n* height compatible with the use of the Thera-Trainer (minimum 120 cm);\n* performance Upper Limb Module 2.0 assessment: Entry level \\>= 2\n\nExclusion Criteria:\n\n* other concomitant genetic diseases;\n* presence of visual impairments that prevent access to the experimental virtual reality protocol;\n* concomitant compromised cardio-respiratory function that contraindicates cycle ergometer training;\n* severe osteoporosis.","6 Years",{"count":240,"type":22},22,[147],"The goal of this clinical trial is to assess the effects of a dual-task, multimodal training program on slowing functional motor decline in children and adolescents with neuromuscular disorders. The main questions it aims to answer are:\n\nDoes Virtual Park slow functional motor decline in children and adolescents with neuromuscular diseases compared with standard therapy?\n\nDoes Virtual Park contribute to increased engagement and improved neuropsychological function?\n\nIf there is a comparison group, Researchers will compare dual-task cycling supported by the Virtual Park application to standard therapy to see whether it improves motor and neuropsychological functions and engagement.\n\nParticipants will undergo two phases:\n\n* Phase 1: 3 months of standard therapy;\n* Phase 2: 3 months of experimental conditions in which patients undergo a rehabilitative intervention with Virtual Park, 3 times a week.",[244,28,245],"Dystrophinopathy","Congenital Myopathies",[247,248,81,249,250,251],"Sports for Persons with Disabilities","Rehabilitation","Dual-Task Exercises","Virtual Reality","Children with Disabilities","2026-05-05",{"date":254,"type":61},"2026-05-12",{"date":63,"type":22},{"date":257,"type":22},"2028-06",{"name":259,"class":166},"Istituto di Sistemi e Tecnologie Industriali Intelligenti per il Manifatturiero Avanzato",4,{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":141,"minAge":269,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":23,"phases":271,"briefSummary":272,"conditions":273,"keywords":4,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":278,"lastUpdatePostDateStruct":279,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":218},"100339334","ecog-bmi-for-motor-and-speech-control-100339334","NCT03698149","ECoG BMI for Motor and Speech Control","A High-Performance ECoG-based Neural Interface for Communication and Neuroprosthetic Control","BRAVO","Inclusion Criteria:\n\n1. Age \\> 21\n2. Limited ability to use upper limbs, based on neurological examination, due to stroke, amyotrophic lateral sclerosis (ALS), multiple sclerosis, cervical spinal cord injury, brainstem stroke, muscular dystrophy, myopathy or severe neuropathy.\n3. Disability, defined by a 4 or greater score on the Modified Rankin Scale, must be severe enough to cause loss of independence and inability to perform activities of daily living.\n4. If stroke or spinal cord injury, at least 1 year has passed since onset of symptoms\n5. Must live within a two-hour drive of UCSF\n\nExclusion Criteria:\n\n1. Pregnancy or breastfeeding\n2. Inability to understand and\u002For read English\n3. Inability to give consent\n4. Dementia, based on history, physical exam, and MMSE\n5. Active depression (BDI \\> 20) or other psychiatric illness (active general anxiety disorder, schizophrenia, bipolar disorder, obsessive-compulsive disorder (OCD), or personality disorders (e.g. multiple personality disorder, borderline personality disorder, etc.)\n6. History of suicide attempt or suicidal ideation\n7. History of substance abuse\n8. Co-morbidities including ongoing anticoagulation, uncontrolled hypertension, cancer, or major organ system failure\n9. Inability to comply with study follow-up visits\n10. Any prior intracranial surgery\n11. History of seizures\n12. Immunocompromised\n13. Has an active infection\n14. Has a CSF drainage system or an active CSF leak\n15. Requires diathermy, electroconvulsive therapy (ECT), or transcranial magnetic stimulation (TMS) to treat a chronic condition\n16. Has an implanted electronic device such as a neurostimulator, cardiac pacemaker\u002Fdefibrillator or medication pump, or presence of any head or neck metallic foreign bodies\n17. Allergies or known hypersensitivity to materials in the Blackrock NeuroPort Array (i.e. silicone, titanium) or the PMT Subdural Cortical Electrode (silicone, platinum iridium, nichrome)","21 Years",{"count":145,"type":22},[147],"Test the feasibility of using electrocorticography (ECoG) signals to control complex devices for motor and speech control in adults severely affected by neurological disorders.",[274,275,276,277,28],"ALS","SCI - Spinal Cord Injury","Stroke","Multiple Sclerosis","2026-04-30",{"date":252,"type":61},{"date":281,"type":61},"2018-11-09",{"date":283,"type":22},"2030-08-15",{"name":285,"class":166},"Karunesh Ganguly",{"id":287,"slug":288,"hasResults":11,"nctId":289,"briefTitle":290,"officialTitle":290,"acronym":291,"eligibilityCriteria":292,"healthyVolunteers":11,"sex":141,"minAge":142,"maxAge":143,"enrollmentInfo":293,"targetDuration":4,"studyType":23,"phases":295,"briefSummary":296,"conditions":297,"keywords":305,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":312,"leadSponsor":314,"locationsCount":218},"100633072","interfacing-with-neurotechnology-to-expand-neural-throughput-intent-100633072","NCT07521930","Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)","INTENT","Inclusion Criteria:\n\n* Complete or incomplete tetraplegia (quadriplegia), tetraparesis (quadriparesis), severe ataxia, or disabling motor impairments in both upper limbs, based on neurological exam. In addition, these motor impairments may be combined with severe motor-related speech impairment (dysarthria or anarthria), as in Locked In Syndrome (LIS) and amyotrophic lateral sclerosis (ALS), including the bulbar variant of ALS.\n* Clinical diagnosis must be established for the etiology of motor impairments, including brainstem stroke\\*, traumatic spinal cord injury (SCI), or progressive and irreversible neuromuscular disease, including muscular dystrophy and motor neuron disease, including amyotrophic lateral sclerosis (ALS). \\*Brain stem stroke is defined as an acute onset of neurological deficit with clinical features of brain stem or cerebellar dysfunction lasting more than 24 hours together with computed tomography (CT) or magnetic resonance imaging (MRI) evidence of ischemic infarction or parenchymal hemorrhage.\n* Candidates with traumatic spinal cord injury must have a complete or incomplete tetraplegia or tetraparesis (ASIA Impairment Scale A, B, C) with an injury level of C6 or higher.\n* Candidates with tetraplegia or tetraparesis from traumatic SCI and other non-progressive neurological disorders must have an upper extremity motor score (UEMS, ISNCSCI) of 7 or less in each of the upper extremities. Candidate must also have less than antigravity strength (\\\u003C 3) throughout the lower limbs.\n* Candidates with progressive conditions with shortened life expectancy, such as ALS, must have less than antigravity strength (\\\u003C3) throughout the upper limbs.\n* Persistence of motor impairments at least 12 months prior to enrollment if due to a non-progressive neurological cause such as stroke or spinal cord injury\n* Meeting surgical safety criteria, including surgical clearance by the participant's primary healthcare provider, study physicians, and any necessary consultants\n* Ability to communicate reliably, such as through speech or eye movement\n* Stable psychosocial support system with caregiver capable of monitoring participant throughout the study\n* Ability and willingness to travel to study location up to five days per week for the duration of the study\n* Ability to understand and comply with study session instructions\n* Corrected visual acuity sufficient for use of computer monitor\n\nExclusion Criteria:\n\n* Psychiatric conditions or cognitive impairments that would interfere with obtaining informed consent or fully participating in study activities.\n* Individuals with active implanted devices, including devices that are incompatible with magnetic resonance imaging (MRI).\n* Contraindications to MRI or anticipated need for an MRI during the study period\n* Medical conditions contraindicating device implantation surgery (for example significant pulmonary, cardiovascular, metabolic, or renal impairments making the surgical procedure unsafe)\n* Chronic anti-coagulation and medical contraindication to temporary suspension for surgery\n* Medical conditions contraindicating chronic device implantation (e.g. osteomyelitis, chronic infection, poorly controlled diabetes, cancer, severe autoimmune disorder, epilepsy, poor wound healing)\n* Participants with dental caries and a significant risk of dental or periodontal infection\n* Chronic oral or intravenous use of steroids or immunosuppressive therapy\n* Active cancer within the past year or ongoing chemotherapy\n* Uncontrolled autonomic dysreflexia within the past 3 months\n* Hydrocephalus with or without an implanted ventricular shunt\n* Other chronic, unstable medical conditions that could interfere with subject participation.\n* Persistent suicidal ideation within the past 12 months.\n* History of substance use disorder within the past year\n* Pregnancy (confirmation through blood test)\n* Nursing an infant, planning to become pregnant, or not using adequate birth control",{"count":294,"type":22},5,[147],"The goal of this clinical trial is to evaluate the safety and preliminary efficacy of an implantable device that records and stimulates different areas of the brain to allow adults affected by disabling paralysis (see Eligibility for more details) to control and receive feedback from assistive devices.",[298,299,30,300,301,28,302,303,304],"Tetraplegia\u002FTetraparesis","Amyotrophic Lateral Sclerosis (ALS)","Brain Stem Stroke","Spinal Cord Injuries (SCI)","Muscular Atrophy, Progressive","Pontine Hemorrhage","Pontine Infarction",[306,307],"Assistive device","Brain Computer Interface","2026-04-02",{"date":310,"type":61},"2026-04-13",{"date":63,"type":22},{"date":313,"type":22},"2028-12",{"name":315,"class":166},"Johns Hopkins University",{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":323,"sex":141,"minAge":142,"maxAge":324,"enrollmentInfo":325,"targetDuration":327,"studyType":328,"phases":4,"briefSummary":329,"conditions":330,"keywords":337,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":344,"lastUpdatePostDateStruct":345,"startDateStruct":347,"completionDateStruct":349,"leadSponsor":351,"locationsCount":218},"100631615","muscle-health-measurements-using-electrical-impedance-myography-100631615","NCT07502989","Muscle Health Measurements Using Electrical Impedance Myography","Convenient Quantification of Myopathic Change in Muscle Via Electrical Impedance Myography","Inclusion Criteria:\n\n* Ages 18-89\n* Evidence of a primary myopathic condition as determined by detailed chart review, including results of genetic testing, serological data, or previous muscle biopsy\n\nExclusion Criteria:\n\n* Inability to lie flat or history of claustrophobia\n* \\>1+ lower extremity edema\n* Presence of multiple other pathologies affecting lower extremity muscles to be studied\n* Pregnancy\n* Contraindications for MRI scanning - e.g. MRI incompatible pacemaker, deep brain stimulator, or lower extremity hardware\n* Contraindications to undergo DXA Scan\n\n  * Any studies\u002Fscans with a radioisotope within the past 15 days\n  * Any imaging with radiographic contrast in the past 7 days\n  * Weight greater than 450 lbs\n  * Calcium supplements or antacids containing calcium in the past 24 hours\n* Severe obesity with BMI \\> 35 kg\u002Fm2, given difficulties fitting in MRI scanner and impact of severe obesity on EIM data\n* Chronic skin conditions with ulcerations which would interfere with EIM electrode contact or be uncomfortable for the participant",true,"89 Years",{"count":326,"type":22},150,"1 Day","OBSERVATIONAL","This study is being done to further develop a device, the mScan, to measure muscle health as compared to measurements of muscle health using MRI (magnetic resonance imaging). This device is held against the skin and uses Electrical Impedance Myography (EIM). EIM uses a very small, noninvasive (e.g. no needles), brief (about 6 seconds), and painless electrical current to measure the muscle. The investigators will look at how the mScan predicts the muscle measurements seen on MRI in people with and without muscle disease. The investigators hope that this can be used in the future as a quick, convenient and less time-consuming way than MRI to assess muscle health. This could be used to measure how well treatments for different muscle disorders are working over a period of time.",[331,28,332,333,334,335,336],"Myopathy","Myositis","Myofibrillar Myopathy","Congenital Myopathy","Distal Myopathy","Myopathies",[338,331,339,340,341,342,343],"Muscle Health","Device","Healthy control","MRI","Electrical Impedance Myography","EIM","2026-03-30",{"date":346,"type":61},"2026-04-03",{"date":348,"type":61},"2025-04-09",{"date":350,"type":22},"2027-09",{"name":352,"class":166},"Beth Israel Deaconess Medical Center",{"id":354,"slug":355,"hasResults":11,"nctId":356,"briefTitle":357,"officialTitle":358,"acronym":4,"eligibilityCriteria":359,"healthyVolunteers":323,"sex":141,"minAge":142,"maxAge":360,"enrollmentInfo":361,"targetDuration":4,"studyType":328,"phases":4,"briefSummary":363,"conditions":364,"keywords":4,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":370,"completionDateStruct":372,"leadSponsor":374,"locationsCount":167},"100567332","observational-study-to-observe-variations-of-gait-parameters-in-patients-with-neuromuscular-diseases-100567332","NCT06666816","Observational Study to Observe Variations of Gait Parameters in Patients With Neuromuscular Diseases","Observational Study for the Identification of Fatigue and Gait Biomarkers in Populations With Neuromuscular Pathologies in the Clinical Context and Daily Life","Inclusion Criteria:\n\n* Ambulant adult patients with genetic diagnosis of muscular dystrophy\u002Fmyopathy (dystrophinopathies, muscular dystrophies and congenital and non-congenital myopathies), of spinal muscular atrophy (SMA) and with molecular diagnosis of Charcot-Marie Tooth 1 or 2.\n* independent walking, even with assistance;\n\nExclusion Criteria:\n\n* Dilated or ischemic heart disease with moderate impairment;\n* Chronic respiratory failure: forced vital capacity (FVC) \\\u003C 40%; more than 5% of nocturnal time spent with peripheral oxygen saturation levels \\\u003C 90.","75 Years",{"count":362,"type":22},120,"This study has the general objective of observing walking parameters during a clinical test to objectively estimate fatigue in patients with neuromuscular diseases. Furthermore, the investigators want to evaluate the feasibility of collecting physical activity in daily life conditions during a one-week monitoring period using a wearable sensor.",[28,336,365,366],"Spinal Muscular Atrophy (SMA)","Charcot Marie Tooth Disease","2026-01-15",{"date":369,"type":61},"2026-01-20",{"date":371,"type":61},"2017-10-27",{"date":373,"type":22},"2026-12",{"name":375,"class":166},"IRCCS Eugenio Medea",{"id":377,"slug":378,"hasResults":11,"nctId":379,"briefTitle":380,"officialTitle":381,"acronym":382,"eligibilityCriteria":383,"healthyVolunteers":11,"sex":141,"minAge":142,"maxAge":143,"enrollmentInfo":384,"targetDuration":4,"studyType":23,"phases":385,"briefSummary":386,"conditions":387,"keywords":4,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":389,"lastUpdatePostDateStruct":390,"startDateStruct":392,"completionDateStruct":394,"leadSponsor":396,"locationsCount":218},"100523324","feasibility-of-the-braingate2-neural-interface-system-in-persons-with-tetraplegia-bg-speech-02-100523324","NCT06094205","Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)","Understanding and Restoring Speech Production Using an Intracortical Brain-computer Interface","BG-Speech-02","Inclusion Criteria:\n\n* Between 18 and 80 years of age\n* Clinical diagnosis of spinal cord injury, brainstem stroke, muscular dystrophy, amyotrophic lateral sclerosis or other motor neuron disorders\n* Complete or incomplete tetraplegia (quadriplegia)\n* Must live within a three-hour drive of the Study site and geographically stable for at least 15 months after enrollment.\n\n(There are additional inclusion criteria)\n\nExclusion Criteria:\n\n* Visual impairment such that extended viewing of a computer monitor would be difficult even with ordinary corrective lenses\n* Chronic oral or intravenous steroids or immunosuppressive therapy\n* Other serious disease or disorder that could seriously affect ability to participate in the study\n\n(There are additional exclusion criteria)",{"count":167,"type":22},[147],"The goal of this study is to improve our understanding of speech production, and to translate this into medical devices called intracortical brain-computer interfaces (iBCIs) that will enable people who have lost the ability to speak fluently to communicate via a computer just by trying to speak.",[150,151,152,153,154,155,388,28],"Locked-in Syndrome","2025-11-26",{"date":391,"type":61},"2025-12-01",{"date":393,"type":61},"2023-10-16",{"date":395,"type":22},"2027-08-31",{"name":165,"class":166},{"id":398,"slug":399,"hasResults":11,"nctId":400,"briefTitle":401,"officialTitle":402,"acronym":4,"eligibilityCriteria":403,"healthyVolunteers":11,"sex":141,"minAge":19,"maxAge":404,"enrollmentInfo":405,"targetDuration":4,"studyType":23,"phases":407,"briefSummary":408,"conditions":409,"keywords":411,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":413,"lastUpdatePostDateStruct":414,"startDateStruct":416,"completionDateStruct":418,"leadSponsor":420,"locationsCount":218},"100602933","fear-of-falling-in-muscular-dystrophy-100602933","NCT07129954","Fear of Falling in Muscular Dystrophy","Fear of Falling in Muscular Dystrophy: Investigation of the Phenomenon and a Multidisciplinary Rehabilitation Approach to Treat it","Inclusion Criteria:\n\n* Diagnosis of muscular dystrophy: myotonic, facio-scapular-humeral, Becker, cingulate, Emery-Dreifuss, and distal;\n* 16 to 65 years of age;\n* Patients with residual walking capacity: functional ambulation category (FAC) at least equal to 1\n* MMSE corrected for age and education of 23,8 points.\n\nSpecific Work Package 2 (WP2) inclusion criterion:\n\n\\- the persistence of Fear Of Falling at 3 months, identified as a score of at least 16 points at the Falls efficacy scale - International (FES-I);\n\nExclusion Criteria:\n\n* The presence of factors that may lead to the assumption that it is a priori impossible to ensure adequate adherence to the proposed treatment;\n* Concurrent management in other rehabilitation centers or participation in other research projects\n* Language barrier;\n* Failure to sign informed consent.","65 Years",{"count":406,"type":22},100,[147],"Primary objectives\n\nWP1: Evaluate the prevalence of FOF in the study population and how this varies over time. Evaluate whether there are relationships between the variables investigated (clinical, motor, cognitive, psychological) and the presence of FOF.\n\nWP2: To evaluate, among those who presented disabling FOF, the effects of two different therapeutic approaches: motor rehabilitation vs. motor rehabilitation plus cognitive-behavioral psychotherapy.\n\nSecondary objectives\n\nWP1: To evaluate whether different profiles defined by specific clinical, motor, cognitive, psychological, and personological characteristics can be characterized among patients with dystrophy and FOF and how these impact functionality, activity, participation, and quality of life.\n\nWP2: Evaluate the effects of cognitive-behavioral therapy (CBT) and a motor treatment on cognitive and psychological aspects, the frequency of falls, and the functional validity.",[410,182,28,248],"Fear of Falling",[410,412,248],"Muscular Dystrophy","2025-08-11",{"date":415,"type":61},"2025-08-19",{"date":417,"type":61},"2025-07-02",{"date":419,"type":22},"2027-08-01",{"name":421,"class":166},"Universita di Verona",{"id":423,"slug":424,"hasResults":11,"nctId":425,"briefTitle":426,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":11,"sex":141,"minAge":428,"maxAge":429,"enrollmentInfo":430,"targetDuration":431,"studyType":328,"phases":4,"briefSummary":432,"conditions":433,"keywords":438,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":446,"completionDateStruct":448,"leadSponsor":450,"locationsCount":218},"100587110","spanish-natural-history-study-for-lama2-muscular-dystrophy-100587110","NCT06924125","Spanish Natural History Study for LAMA2 Muscular Dystrophy","Inclusion Criteria:\n\n* All patients with compatible clinical presentation and identification of 2 pathogenic variants in LAMA2, or muscle biopsy with decreased laminin alpha2 protein and at least one pathogenic variant\n* Signed informed consent by the Legal Authority Responsible and\u002For assent by the subject (starting from 6 years old)","0 Minutes","100 Years",{"count":406,"type":22},"5 Years","The objective of this natural history study is to comprehensively characterize the disease progression and clinical features of LAMA2-related dystrophies (LAMA2-RD) in the pediatric population. The study aims to establish a well-defined cohort of patients in Spain, enabling long-term follow-up and facilitating recruitment for future clinical trials.",[434,435,436,28,437],"LAMA2-MD (Merosin Deficient Congenital Muscular Dystrophy, MDC1A)","Merosin Deficient CMD (Full or Partial)","Merosin Deficient Congenital Muscular Dystrophy","Cohort Studies",[439,440,441,195,442],"Merosin","LAMA2","Laminin","natural history","2025-04-05",{"date":445,"type":61},"2025-04-11",{"date":447,"type":61},"2021-07-27",{"date":449,"type":22},"2030-07-01",{"name":451,"class":166},"Hospital Universitari Vall d'Hebron Research Institute"]